Protego Biopharma just pulled in a $130M Series B that did more than close, it resonated. When Novartis Venture Fund and Forbion anchor a round this oversubscribed, it means the room smelled conviction, not conjecture. Protego Biopharma is stepping into the AL amyloidosis arena with PROT-001, and the move feels less like a gamble and more like a precision strike at the biochemical chaos that has defined this rare disease for far too long. The company has been sharpening its edge since 2017, built on the shoulders of co-founders Jeffery W. Kelly, PhD, Xin Jiang, PhD, and Richard Labaudiniere, PhD, whose work helped give the world tafamidis, a drug that turned into a $3.3B powerhouse for Pfizer. That is not legacy, that is gravitational pull.
The shift in 2024, when Brent Warner stepped in as CEO, marked the moment Protego Biopharma graduated from scientific pedigree to clinical execution. Warner’s 15+ years across Novartis, BioMarin, Biogen, and Poseida Therapeutics give him the kind of operator DNA this field does not often get. Pair that with the technical firepower of Mike Petrassi, PhD, and the business precision of Christopher Weyrer, MD, PhD, and you have a leadership team built for velocity rather than theatrics.
PROT-001 entered Phase 1 earlier this year in a 102 participant, randomized, double blind clinical study in Australia. The goal is simple on paper and incredibly complex in practice, stabilize lambda light chains before they misfold, prevent the toxic deposits before they form, and give patients an actual chance at organ preservation rather than damage control. The AmyLite assay plays the role most platforms wish they had, a clean, plasma based biomarker confirming target engagement in real time. Investors love clarity, regulators love measurable biology, and patients love knowing the science is not guessing.
The AL amyloidosis market sits near $3.8B today and is projected to hit $15B by 2035 with a 13.26% CAGR. A disease with 4,500 new US cases a year and 12k to 14k living patients is not a small market disguised as rare, it is an underserved one waiting for a therapy that does more than chase symptoms. PROT-001 steps in with prevention as its thesis, not repair. That alone explains why Omega Funds, Droia Ventures, YK Bioventures, and Digitalis Ventures joined the returning believers at Vida Ventures, MPM BioImpact, Lightspeed Venture Partners, and Scripps Research. This round signals that Protego Biopharma is not just marching toward pivotal trials, it is sculpting a path where protein misfolding finally meets its match and where a company named Protego truly lives up to the promise of protection at the molecular level.
Startups Startup Funding Venture Capital Series B Biotech Biopharma Healthcare HealthTech Technology Innovation Tech Ecosystem Startup Ecosystem
